Sulbactam Efficacy Against Acinetobacter baumannii Pneumonia
Author Information
Author(s): Abouelhassan Yasmeen, Kuti Joseph L, Nicolau David P, Abdelraouf Kamilia
Primary Institution: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA
Hypothesis
What are the efficacy targets for sulbactam in epithelial lining fluid against Acinetobacter baumannii pneumonia?
Conclusion
The study found that the maximum FDA approved dose of sulbactam provides effective coverage for certain isolates, but higher doses are needed for others.
Supporting Evidence
- The study established sulbactam efficacy targets in epithelial lining fluid for Acinetobacter baumannii pneumonia.
- Median %fT > MIC required for 1-log kill in resistant isolates was significantly higher than in susceptible isolates.
- The study demonstrated that higher doses of sulbactam provide better efficacy against certain bacterial phenotypes.
Takeaway
This study looked at how well a medicine called sulbactam works against a type of bacteria in the lungs, showing that different doses are needed for different types of bacteria.
Methodology
The study used a neutropenic murine pneumonia model to assess sulbactam pharmacokinetics and pharmacodynamics.
Limitations
The study relied on data from healthy volunteers to estimate drug penetration, which may differ in infected patients.
Participant Demographics
The bacterial isolates were collected from various geographical locations globally between 2018 and 2021.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website